Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab

IF 4.4 2区医学 Q1 ONCOLOGY

Lung Cancer Pub Date : 2025-08-12 DOI:10.1016/j.lungcan.2025.108709

Sawana Ono , Hirokazu Taniguchi , Koji Kuroda , Teppei Hashimoto , Asuka Okada , Yasuhiro Goto , Hidenori Kitai , Yoichi Nakamura , Shinsuke Ogusu , Tetsunari Hase , Takayo Ota , Noriyuki Ebi , Makoto Furugen , Taishi Harada , Yoshiaki Kinoshita , Takaki Mizoguchi , Katsumi Nakatomi , Yoshifumi Soejima , Takahiro Yamada , Shinnosuke Takemoto , Hiroshi Mukae

{"title":"Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab","authors":"Sawana Ono , Hirokazu Taniguchi , Koji Kuroda , Teppei Hashimoto , Asuka Okada , Yasuhiro Goto , Hidenori Kitai , Yoichi Nakamura , Shinsuke Ogusu , Tetsunari Hase , Takayo Ota , Noriyuki Ebi , Makoto Furugen , Taishi Harada , Yoshiaki Kinoshita , Takaki Mizoguchi , Katsumi Nakatomi , Yoshifumi Soejima , Takahiro Yamada , Shinnosuke Takemoto , Hiroshi Mukae","doi":"10.1016/j.lungcan.2025.108709","DOIUrl":null,"url":null,"abstract":"<div><div>There is limited evidence regarding the second-line treatment for patients with unresectable, advanced, or metastatic pleural mesothelioma receiving first-line nivolumab plus ipilimumab combination immunotherapy. Although chemotherapy with pemetrexed and a platinum-based agent is empirically administered as the second-line treatment in clinical practice, its effect in patients after nivolumab plus ipilimumab remains unclear. Therefore, this retrospective observational study aimed to elucidate the efficacy of pemetrexed plus platinum therapy as a second-line treatment for pleural mesothelioma after first-line nivolumab-ipilimumab immunotherapy. Forty-three patients with unresectable or advanced pleural mesothelioma were enrolled in this study. Median overall survival was 17.1 months (95 % confidence interval [CI]: 9.3- not estimable), and median progression-free survival was 5.7 months (95 % CI: 3.9–11.9). The one-year overall survival rate was 62.8 % (95 % CI: 45.0–76.3) and one-year progression-free survival rate was 26.2 % (95 % CI: 10.4–45.2). In patients with measurable lesions, the overall response rate was 30.3 % and disease control rate was 69.7 %. These results are similar to those of previous studies on pemetrexed-platinum for pleural mesothelioma in first-line settings, suggesting that pemetrexed-platinum therapy can be considered an appropriate choice for the second-line treatment of mesothelioma after immunotherapy.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"207 ","pages":"Article 108709"},"PeriodicalIF":4.4000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169500225006014","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

There is limited evidence regarding the second-line treatment for patients with unresectable, advanced, or metastatic pleural mesothelioma receiving first-line nivolumab plus ipilimumab combination immunotherapy. Although chemotherapy with pemetrexed and a platinum-based agent is empirically administered as the second-line treatment in clinical practice, its effect in patients after nivolumab plus ipilimumab remains unclear. Therefore, this retrospective observational study aimed to elucidate the efficacy of pemetrexed plus platinum therapy as a second-line treatment for pleural mesothelioma after first-line nivolumab-ipilimumab immunotherapy. Forty-three patients with unresectable or advanced pleural mesothelioma were enrolled in this study. Median overall survival was 17.1 months (95 % confidence interval [CI]: 9.3- not estimable), and median progression-free survival was 5.7 months (95 % CI: 3.9–11.9). The one-year overall survival rate was 62.8 % (95 % CI: 45.0–76.3) and one-year progression-free survival rate was 26.2 % (95 % CI: 10.4–45.2). In patients with measurable lesions, the overall response rate was 30.3 % and disease control rate was 69.7 %. These results are similar to those of previous studies on pemetrexed-platinum for pleural mesothelioma in first-line settings, suggesting that pemetrexed-platinum therapy can be considered an appropriate choice for the second-line treatment of mesothelioma after immunotherapy.

查看原文本刊更多论文

培美曲塞加铂作为纳武单抗加伊匹单抗治疗胸膜间皮瘤患者的二线治疗

对于不可切除、晚期或转移性胸膜间皮瘤患者接受一线纳沃单抗+伊匹单抗联合免疫治疗的二线治疗，证据有限。尽管在临床实践中，培美曲塞和铂类药物联合化疗作为二线治疗的经验，但其在纳武单抗联合伊匹单抗后的疗效尚不清楚。因此，本回顾性观察性研究旨在阐明培美曲塞加铂治疗作为一线尼武单抗-伊匹单抗免疫治疗后胸膜间皮瘤的二线治疗的疗效。43例不可切除或晚期胸膜间皮瘤患者参加了这项研究。中位总生存期为17.1个月（95%可信区间[CI]: 9.3-不可估计），中位无进展生存期为5.7个月（95% CI: 3.9-11.9）。1年总生存率为62.8% (95% CI: 45.0-76.3)， 1年无进展生存率为26.2% （95% CI: 10.4-45.2）。在可测量病变的患者中，总有效率为30.3%，疾病控制率为69.7%。这些结果与以往关于培美塞铂治疗一线胸膜间皮瘤的研究结果相似，提示培美塞铂治疗可被认为是免疫治疗后二线间皮瘤治疗的合适选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lung Cancer 医学-呼吸系统

CiteScore

9.40

自引率

3.80%

发文量

407

审稿时长

25 days

期刊介绍： Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.